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Abstract
Introduction The inflammatory process of atherosclerosis is
associated with several pathophysiological reactions within
the vascular wall. The arachidonic acid released by
phospholipase A2 serves as substrate for the production of
a group of lipid mediators known as the leukotrienes, which
induce pro-inflammatory signaling through activation of
specific BLT and CysLT receptors.
Discussion Leukotriene signaling has been implicated in
early lipid retention and foam cell accumulation, as well as
in the development of intimal hyperplasia and advanced
atherosclerotic lesions. Furthermore, the association of
leukotrienes with degradation of extracellular matrix has
suggested a role in atherosclerotic plaque rupture. Finally,
studies of either myocardial or cerebral ischemia and
reperfusion indicate that leukotriene signaling in addition
may be involved in the development of ischemic injury.
Conclusion Both leukotriene synthesis inhibitors and leu-
kotriene receptor antagonists have been suggested to induce
beneficial effects at different stages of the atherosclerosis
process.
Key words Inflammation . Intimal hyperplasia .
Leukotriene receptors . Lipoxygenase .Myocardial infarction
Leukotriene biosynthesis from phospholipids
The proinflammatory lipid mediators known as the leuko-
trienes (LTs) were initially described by their bioactivity
referred to as Slow Reacting Substance of Anaphylaxis
(SRS-A; [1]), which was discovered after challenge of
animal lungs with snake venom [2]. This observation has
subsequently been explained by LT synthesis induced by
phospholipase A2 (PLA2), which is the major enzymatic
component of snake venom. PLA2 consists of several
groups of both secretory and cytosolic forms [3]. The
cytosolic PLA2 (cPLA2) displays a calcium-dependent
activation, and has a specificity for phospholipids with
arachidonic acid (AA) bound at the sn-2 position. It is the
resulting liberation of AA, which provides the substrate for
the formation of LTs (Fig. 1) [4]. The subsequent enzymatic
step, lipoxygenation of AA by 5-lipoxygenase (5-LO) and
its activating protein FLAP (Fig. 1), yields the unstable
product LTA4 [4]. Subsequently, the LT synthesis follows
two distinct pathways. Hydrolysis of LTA4 leads to
formation of LTB4, a potent chemoattractant and leukocyte
activator [5]. On the other arm of the pathway, LTA4 is
conjugated with glutathione by the action of LTC4 synthase
(Fig. 1). The latter enzymatic step leads to the formation of
LTC4, D4 and E4 (collectively referred to as the cysteinyl-
LTs) (Fig. 1), which have been associated with broncho-
and vasoconstriction [5].
Although the major interest for PLA2 in the context of
atherosclerosis has been focused on their effects on
lipoproteins [6], the participation of PLA2 in leukotriene
formation may result in additional proatherogenic signaling
from this enzymatic pathway. While the effects of different
PLA2 inhibitors on leukotriene biosynthesis today remains
largely unknown, specific interventions within the LT
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signaling have indicated beneficial effects on atherosclero-
sis development.
Leukotriene receptors
The biological actions of the LTs are transduced through 7-
transmembrane G-protein-coupled receptors (GPCR). The
two arms of the LT pathway have distinct receptors referred
to as BLT receptors (activated by LTB4) and CysLT
receptors (activated by the cysteinyl-LTs), respectively
(Fig. 1) [5]. While the BLT receptors are denoted BLT1
and BLT2, for the high and low affinity receptor subtypes,
respectively, receptors activated by the cysteinyl-LTs are
characterized by their sensitivity to available antagonists
and are referred to as CysLT1 and CysLT2 [7, 8] The latter
nomenclature probably only in part describes the cysteinyl-
LT signaling, since limitation of the currently available
CysLT receptor antagonists [8], as well as cross-reactivities
between CysLT and purinoreceptors [9] indicate more
complex receptor ligation properties for cysteinyl-LTs.
Proinflammatory leukotriene signaling
in atherosclerosis
Although the use of statins may decrease both systemic and
local inflammation in atherosclerosis, a potential further
benefit could be anticipated by specific anti-inflammatory
agents targeting key immune reactions in the atherosclero-
sis process. Ever since the concept of inflammation and
atherosclerosis was raised, a number of inflammatory
mediators has been explored as potential therapeutic targets
in this disease [10]. The inflammatory response induced
through LT signaling may be of particular interest in this
context since several drugs targeting this pathway are either
available or under development, as indicated in Fig. 1 [11].
Although there is a long tradition of treating asthma with
anti-LTs [12], very little is known about the long term
effects of the anti-asthmatic LT inhibitors on cardiovascular
outcome. Some interesting indications can however be
obtained from retrospective studies. For example, a ran-
domized controlled trial of placebo versus either the
CysLT1 receptor antagonist montelukast (Fig. 1) or theoph-
ylline, reported significantly lower levels of CRP in
montelukast-treated patients with severe asthma [13].
Although no follow-up of those patients was performed in
terms of cardiovascular disease, a systemic anti-inflamma-
tory effect of montelukast could indicate potential benefi-
cial effects.
Although asthma may not be a classical co-morbidity of
atherosclerosis, LTs have been implicated as potential
mediators of cardiovascular risk in other inflammatory
diseases. For example, in studies of patients with chronic
obstructive pulmonary disease (COPD), the prevalence of
ischemic heart disease is approximately twofold higher
compared with the general population [14]. The beneficial
effects of anti-LTs in reducing air-flow obstruction in
asthma has been reproduced in COPD patients [14].
Furthermore, short time treatment with the LT synthesis
inhibitor BAYx1005/DG031 (Fig. 1) has been evaluated in
both COPD and in patients with a history of myocardial
infarction [15, 16]. Although the treatment protocols used
in both the latter two studies resulted in only modest
inhibition of LTB4 concentrations in either sputum or
stimulated whole blood, the results suggested a tendency
for decrease of inflammatory markers [15, 16]. Despite the
limitations (small patient numbers, short time treatments,
limited LT inhibition etc), these studies provide an initial
suggestion as to a potential beneficial effect of an anti-LT
treatment in atherosclerosis.
In addition to the lungs, the oral cavity may be another
source of low grade chronic inflammation as a substrate for
atherosclerosis development. Periodontal disease is for
example associated with the development of early athero-
sclerotic lesions in the carotid artery [17], and an increased
risk of stroke [18] and myocardial infarction [19]. The
notion of LTs as common mediators of atherosclerosis and
periodontal disease was recently suggested in a study
associating high levels of cysteinyl-LTs in gingival crev-
icular fluid with an increased carotid artery wall thickness
Fig. 1 The formation of leukotrienes (LTs) through the 5-lipoxyge-
nase pathway of arachidonic acid metabolism, and the effects of LT
inhibitors in different contexts. Gray ovals indicate the enzymes
involved in LT biosynthesis; Phospholipase A2 (PLA2), 5-lipoxyge-
nase (5-LO) with its activating protein (FLAP), LTA4 hydrolase
(LTA4H), and LTC4 synthase (LTC4S). Rectangles indicate the LT
receptors. Examples of LT synthesis inhibitors are indicated by black
triangles, whereas examples of LT receptor antagonists are indicated
by open triangles
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[20]. Chronic inflammation in the oral cavity can also be
measured in the saliva, in which high LT concentrations
have been demonstrated [21, 22], and reported to be
inhibited by zileuton [23], an anti-asthmatic LT synthesis
inhibitor (Fig. 1). Although hitherto not evaluated in the
context of cardiovascular disease, those studies not only
suggest the oral cavity as a site of chronic inflammation,
but also indicate that the saliva may be a possible source for
measures of LTs as biomarkers.
As a final example of co-morbidities in which LTs could
act as a potential link to atherosclerosis, subjects with
obstructive sleep apnea (OSA) exhibit significantly higher
LTB4 synthesis in ex vivo stimulated neutrophils compared
with control subjects [24]. Interestingly, the LTB4 produc-
tion in subjects with OSAwas significantly correlated to the
carotid artery diameter in the latter study [24], further
supporting the notion of LTs as potential mediators of the
increased cardiovascular risk associated with different
inflammatory conditions.
In addition to the studies implicating leukotrienes in co-
morbidities of atherosclerosis, studies of genetic poly-
morphisms have established significant associations for
the LT pathway with early signs of atherosclerosis [25, 26],
as well as the development of stroke and myocardial
infarction [27, 28]. Furthermore, mechanistic studies have
implicated the LT pathway at several different stages of the
atherosclerosis process (Fig. 2) [29]. For example, LT
signaling has been suggested to be involved in the initiation
of atherosclerosis, through both lipid retention and thick-
ening of the vascular wall, as well as in the changes of the
endothelial homeostasis that characterize early atheroscle-
rosis (Fig. 2). Subsequently, the potent LT-induced immu-
nostimulatory actions have indicated a key role in atheroma
development. Furthermore, some studies have indicated a
role for the LT pathway in plaque rupture, causing
thrombosis and vessel occlusion (Fig. 2). The plaque
rupture induces ischemia in distal organs, such as the brain
and the myocardium, and the contribution of LT signaling
in stroke and myocardial infarction has been studied in
models of ischemia and reperfusion. Taken together,
atherosclerotic processes deteriorating healthy vessels and
causing organ damage may at each stage represent a
putative target for anti-LT therapy. The next sections of
this review will focus on how the LT pathway potentially
may interact at those different stages of atherosclerosis
development, and eventually its ischemic complication,
such as myocardial infarction and stroke (Fig. 2).
Lipid retention and modification
The early sign of lipid retention within the vascular wall is
referred to as fatty streaks, which appear early in life and
may either disappear or develop into more advanced
atherosclerotic lesions (Fig. 2) [10]. Fatty streaks consist
mainly of lipid laden macrophages, or foam cells [10]. As
lipids are taken up into the vascular wall, they undergo
oxidative modifications [10]. Several studies support a
lipoxygenase-mediated oxidation of low density lipopro-
teins (LDL) [30, 31], mainly mediated trough the 15-
lipoxygenase (15-LO) pathway [32]. However, recent
findings have indicated an absence of 15-LO expression
within atherosclerotic lesions [33], hence questioning its
role as a driver of LDL oxidation in vivo. According to the
latter study, 5-LO is the main lipoxygenase expressed
within atherosclerotic lesions [33]. Since the role of 5-LO
in LDL oxidations appears less convincing compared with
the actions of 15-LO [34, 35], the atherogenic role of 5-LO
may rather be dependent on its participation in the
biosynthesis of LTs, and the pro-inflammatory signaling
transduced through LT receptor activation [29]. The latter
notion is supported by findings in atherosclerotic apolipo-
Fig. 2 The potential involve-
ment of leukotrienes in the
different stages of the athero-
sclerosis process eventually
leading to cerebral and myocar-
dial ischemia. Abbreviations:
SMC smooth muscle cells, MMP
matrix metalloproteinase, I/R is-
chemia and reperfusion
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protein E (ApoE) knockout mice in which either genetic or
pharmacological targeting of the BLT1 receptor reduces
lipid accumulation and foam cell infiltration [36–38].
Intimal hyperplasia
Another sign of early atherosclerosis is the thickening of
the inner muscular layer of the vascular wall, which is
referred to as intimal hyperplasia (Fig. 2) [10]. Cysteinyl-
LT signaling through CysLT receptors mediates prolifera-
tion and migration of vascular smooth muscle cells (SMCs)
[5]. In addition, the class of CysLT1 receptor antagonists
used in the treatment of asthma (Fig. 1) inhibits intimal
hyperplasia after vascular injury in different animal models
[5, 39]. Recently, it was discovered that SMCs within
human atherosclerotic lesions also express receptors for
LTB4 [38, 40], mediating proliferation and migration of
coronary artery SMCs [40]. The important signaling
through these receptors has been supported by findings in
ApoE−/− mice with a targeted BLT1 receptor, which have
fewer SMCs in their lesions [38]. Furthermore, BLT
receptor antagonism reduces intimal hyperplasia after
vascular injury in rats [5, 40]. Taken together, the LT-
induced stimulation of SMCs suggests their involvement in
the intimal hyperplasia associated both with early athero-
sclerosis and in-stent restenosis after coronary interventions
[5].
Endothelial dysfunction
While in healthy individuals, the endothelium contributes to
vascular homeostasis, atherosclerosis is characterized by a
dysfunctional endothelium (Fig. 2). Cysteinyl-LT activation
of endothelial cells have been reported to be transduced
through constitutively expressed CysLT2 receptors [41, 42]
coupled to a release of relaxant factors [5]. However, while
a proinflammatory environment down-regulates CysLT2
receptor expression in human umbilical vein endothelial
cells (HUVECs) [42], CysLT1 receptor expression is
induced in HUVECs under such conditions [43]. Further-
more, studies of isolated arteries have demonstrated
endothelium-dependent contractions through CysLT1 recep-
tor signaling [44, 45]. Taken together, those observations
suggest that a balance of CysLT receptor subtype expres-
sion may determine the LT-induced endothelium-dependent
vasomotor responses. The latter notion has in addition
received support from animal models. Directed endothelial
expression of the human CysLT2 receptor in mice induces
an enhanced NO production in response to LTC4, but does
not change baseline systemic blood pressure compared with
wild type mice [46]. Furthermore, although the LT synthesis
inhibitor MK-886 (Fig. 1) does not alter mean arterial blood
pressure in spontaneously hypertensive rats [47], this
treatment prevents the rise in blood pressure observed in
rats chronically treated by an NO synthesis inhibitor [48].
In summary, data from several studies using different in
vivo and in vitro models suggest that cysteinyl-LT signaling
may provide a key balance between a release of endothe-
lium-dependent relaxant and constricting factors.
In contrast to this relatively extensive exploration of
CysLT receptor signaling on endothelial cells, less is known
about the signaling of the other arm of the LT pathway,
through BLT receptors, in this context. Although healthy
human arteries may not express receptors for LTB4, an
endothelial BLT1 receptor expression is induced in athero-
sclerotic lesions [40]. Findings in animal models have in
addition suggested that LTB4-signaling through the BLT1
receptor may also be associated with an endothelium-
dependent release of vasoactive factors [49, 50].
In addition to direct action on the vascular tone, LT-
induced activation of endothelial cells may also lead to
changes in the transcriptional activity. In HUVECs, LTD4
induces endothelial P-selectin expression through CysLT2
receptor activation [51]. Furthermore, the CXC chemokines
CXCL-2 [52] and IL-8 [53] are found among the most up-
regulated genes after stimulation of HUVECs with LTD4.
The latter findings suggest that LT-induced activation of the
endothelium in addition may participate in the starting point
of the immune activation associated with the atheroma
formation.
Atherosclerotic plaque formation
Foam cell accumulation and altered endothelial homeostasis
will induce progressive recruitment of different populations
of immune cells to the vascular wall, and eventually lead to
the formation of the atherosclerorotic plaque, or atheroma
(Fig. 2) [10]. This process is characterized not only by a
reduction of the arterial lumen size, but also by the formation
of a necrotic lipid core surrounded by a fibrous cap of
extracellular matrix and SMCs (Fig. 2) [10]. The chemo-
attractant activity induced by LTB4 through BLT1 and BLT2
receptors expressed on monocytes may play an important
role in the continued accumulation of macrophages at the
site of the initial foam cell infiltration [36]. Since macro-
phages represent a major source of 5-LO in the cardiovas-
cular system, LTB4-induced monocyte recruitment could
potentially further exacerbate the inflammatory activity at
sites of atherosclerotic lesions. Furthermore, LTB4 also
induces chemotaxis of other immune cells, such as T-
lymphocytes, which accumulate in the vicinity of 5-LO-
positive macrophages [52]. In a mouse model combining
hyperinflammation and hyperlipidemia, through selective
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abrogation of T-cell TGFβ signaling in ApoE−/− mice, a
stimulatory effect of activated T-lymphocytes on LT synthe-
sis has been demonstrated [54]. Activated T-lymphocytes up-
regulate the expression of FLAP in macrophages, leading to
an increased LTB4 formation [54]. The increased LTB4
formation that results from both monocyte recruitment and
T-lymphocyte-mediated FLAP up-regulation, may lead to a
vicious circle involving progressive recruitment of inflam-
matory cells and a maintained immune activation within the
atherosclerotic lesion [29, 54]. Selective targeting of LTB4
signaling could be key in blocking this vicious circle, as
suggested by the capacity of different anti-leukotriene
treatment strategies to reduce atheroma macrophage and T-
lymphocyte content in hyperlipidemic mice (Fig. 1) [29].
Plaque rupture
Rupture of the fibrous cap will expose the content of the
atheroma to the circulation, leading to platelet activation and
thrombotic occlusion of the arterial lumen [10]. In a
coronary artery, this process will lead to myocardial ischemia
whereas in the cerbrovasculature, cerebral ischemia will
occur (Fig. 2). The role of leukotrienes in plaque rupture has
been suggested through transcriptional profiling of carotid
endarterectomies, in which the constituents of the leukotri-
ene pathway are expressed at higher levels in specimens
obtained from patients with recent clinical signs of cerebral
ischemia compared with asymptomatic patients [55]. One of
the key components in plaque instability and rupture is the
degradation of extracellular matrix by specific matrix metal-
loproteinases (MMPs) [56]. The production, secretion and
activation of MMPs may be dependent on the generation of
endogenous LTs, as suggested by the co-localization of 5-LO
with MMPs in human carotid atherosclerotic lesions [55].
The latter observation was recently extended to endarterec-
tomies derived from diabetic patients, in which 5-LO
expression and LTB4 production was associated with
increased levels of MMP protein [57]. Furthermore, smokers
exhibit a significant correlation between LTB4 concentra-
tions and MMP-9 activity in saliva [21]. Taken together,
those studies suggest that both LTs and MMPs are
simultaneously increased during an inflammatory response.
Those observations provide an initial suggestion of
inhibited protease activities after pharmacological inhibition
of LT signaling, with potential therapeutic implications for
the prevention of plaque rupture.
Myocardial ischemia
In support of a link between leukotrienes and coronary plaque
rupture, increased levels of urinary LTs have been reported in
patients with acute coronary syndromes [58]. However,
whether urinary LTs are markers of plaque rupture, or rather
reflects the inflammatory response associated with myocar-
dial ischemia remains to be established. Experimental
myocardial ischemia indeed induces increased LT production
[59, 60]. Several studies of transient ischemia in isolated
perfused hearts derived from either rats or rabbits have in
addition indicated an improved myocardial recovery after LT
inhibition [59–62]. However, the results of in vivo ischemia
and reperfusion have provided contradictory results. Either
CysLT1 receptor antagonism or LT synthesis inhibition
induces a protective effect after myocardial ischemia fol-
lowed by reperfusion in rabbits and cats, respectively [60,
63]. In contrast, different LT receptor antagonists have been
reported not to alter the infarct size after myocardial ischemia
and reperfusion in rats [61, 64], and both positive and neutral
effects have been reported for LT synthesis inhibitors in dogs
[65, 66]. In mice subjected to coronary ligation and
reperfusion, the infarct size is not affected by either 5-LO
knock out or CysLT receptor antagonism [67, 68]. In the
latter model, 5-LO deficient mice have been reported to
exhibit an even increased neutrophil infiltration and proin-
flammatory gene expression within the infarction area
compared with wild type mice [67]. Although the these
results raise a doubt as to the role of LTs in myocardial
ischemia, a recent study of transgenic mice expressing a
human endothelial CysLT2 receptor, have reported an
increased infarct size and leukocyte infiltration resulting
from signaling trough this receptor [67]. However, the
absence of atherosclerosis in the latter studies may limit the
extrapolation of the findings to human coronary syndromes.
As discussed above, the endothelial CysLT2 receptor is
rapidly down-regulated by pro-inflammatory stimuli in vitro
[42]. Furthermore, microcirculatory changes induced during
atherosclerosis have in addition been suggested by the
exaggerated leukocyte recruitment and plasma leakage after
ischemia and reperfusion in hypercholesterolemic LDLR−/−
mice [69]. Although a role for LTs in this enhanced response
was not established in the latter study [69], the LTB4-induced
leukocyte adhesion and migration, as determined by intravital
microscopy in postcapillary venules, are significantly en-
hanced in LDLR−/− compared with wild type mice [70].
Cerebral ischemia
The notion of LT production in the ischemic brain was firstly
raised by studies in gerbils [71], in which inhibitors of LT
synthesis limit the damage after transient cerebral ischemia
[72]. Subsequent studies in rats have associated beneficial
effects with the cysteinyl-LT arm of the AA metabolism. For
example, anti-asthmatic CysLT1 receptor antagonists, such as
pranlukast and montelukast, reduce the effects of both focal
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and global ischemia provoked through either transient or
permanent cerebral artery occlusion in rats [9, 73, 74]
(Fig. 1). Interestingly, a purino-like GPRC named GPR17
has been shown to in addition to uracil nucleotides, also be
activated by LTD4 and LTC4 [9]. This potentially dual
CysLT and purinoreceptor is up-regulated in the ischemic
brain, and silenced receptor expression in vivo mimics the
neuroprotective effects of montelukast after 48 h of
permanent focal ischemia.
Conclusion
The proinflammatory signaling induced by LT receptor
ligation has been implicated at several stages of the
atherosclerosis process, and may represent a putative target
in the design of novel anti-inflammatory strategies to
prevent myocardial infarction and stroke. Based on findings
in different animal models of atherosclerosis [29], benefi-
cial effects could be anticipated by anti-LT treatments.
Although some findings in humans based on either genetic
associations [25–28] or LT measurements in different
patient populations [20, 21, 24, 58], support this notion, it
may currently be premature to conclude on what exact
mechanisms to target in human disease. Some interesting
information can however be obtained through studies of
other pathologies in which anti-LT treatments already have
been evaluated [12, 14]. In the latter context, the effects of
LT inhibition is of particular interest in the context of
diseases associated with an increased cardiovascular risk,
such as COPD and periodontitis [14, 20]. The challenge is
now to extrapolate experimental findings to a clinical
setting in order to identify patients groups that would
benefit from an inhibited LT signaling.
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